Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2014-01-01

Summary

To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies

• Phase: Phase 1

Details

• Lead Sponsor: Merrimack Pharmaceuticals
• Collaborator: Sanofi
• Treatments: Antibodies, Monoclonal; Carboplatin; Gemcitabine; Pemetrexed